Literature DB >> 26806060

Multidisciplinary Approach for Acromegaly: A Single Tertiary Center's Experience.

Ozlem Haliloglu1, Enis Kuruoglu2, Hande Mefkure Ozkaya1, Fatma Ela Keskin1, Omur Gunaldi2, Buge Oz3, Nurperi Gazioglu2, Pinar Kadioglu1, Necmettin Tanriover4.   

Abstract

BACKGROUND: Acromegaly is a multisystemic disease that requires a multidisciplinary approach. The aim of this study was to determine early and late remissions of patients who underwent surgery at our center and to evaluate relations between pathologic and radiologic properties of adenoma and medical and radiosurgical treatments with remissions.
METHODS: The medical records of 103 patients with acromegaly who underwent endoscopic endonasal transsphenoidal surgery in Cerrahpasa Medical Faculty, Istanbul University, between 2007 and 2014 were reviewed. Clinical, biochemical, radiologic, and pathologic properties were determined.
RESULTS: The total median follow-up time was 38 months [interquartile range: 24-53.5 months]. Thirty-two percent of the adenomas were microadenomas and 68% were macroadenomas The early remission rate was 51.5% and late remission was 75.2%. The sellar floor invasion was significantly lower in patients with early and late remissions (P = 0.01 and P = 0.009, respectively). The initial growth hormone (GH; P < 0.001), first-day GH (P = 0.03), 3-month GH (P = 0.001), insulin-like growth factor-1 (P = 0.004), and 6-month insulin-like growth factor-1 (P = 0.02) levels were significantly greater in patients with sellar floor invasion. The late remission rates (P = 0.004) were greter and reoperation needs (P = 0.05) were lower in patients with Ki-67 <3% than in patients with ≥3%. Seventy (68.6%) patients needed medical therapy during follow-up.
CONCLUSIONS: Late remission was achieved using a multidiciplinary approach in 75.2% of 103 patients with acromegaly, and young age, male sex, high Ki-67 and mitosis indices, and cavernous sinus and sellar-floor invasion had negative effects on clinical and biochemical control of the disease.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acromegaly; Early remission; Late remission; Proliferation indices

Mesh:

Year:  2016        PMID: 26806060     DOI: 10.1016/j.wneu.2015.12.092

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies.

Authors:  Letícia P Leonart; Fernanda S Tonin; Vinicius L Ferreira; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  Endocrine       Date:  2018-08-25       Impact factor: 3.633

2.  Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry.

Authors:  Leila Hedayati Zafarghandi; Mohammad Ebrahim Khamseh; Milad Fooladgar; Shahrzad Mohseni; Mostafa Qorbani; Nahid Hashemi Madani; Mahboobeh Hemmatabadi; MohammadReza Mohajeri-Tehrani; Nooshin Shirzad
Journal:  J Diabetes Metab Disord       Date:  2020-04-05

3.  Early postoperative prediction of both disease remission and long-term disease control in acromegaly using the oral glucose tolerance test.

Authors:  Kiyohiko Sakata; Yui Nagata; Nobuyuki Takeshige; Jin Kikuchi; Masato Shikata; Kenji Ashida; Masatoshi Nomura; Motohiro Morioka
Journal:  Hormones (Athens)       Date:  2021-03-18       Impact factor: 2.885

4.  Association of pre- and postoperative αKlotho levels with long-term remission after pituitary surgery for acromegaly.

Authors:  Marian Christoph Neidert; Anna Maria Zeitlberger; Henning Leske; Oliver Tschopp; Lisa Sze; Cornelia Zwimpfer; Peter Wiesli; David Bellut; René-Ludwig Bernays; Elisabeth Jane Rushing; Christoph Schmid
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

5.  Associations of Ki-67 Labeling Index with Clinical and Paraclinical Features of Growth Hormone-Secreting Pituitary Adenomas: A Single Center Report from Iran.

Authors:  Shahrzad Mohseni; Maryam Aboeerad; Farshad Sharifi; Seyed Mohammad Tavangar; Mohammadreza Mohajeri-Tehrani
Journal:  Int J Endocrinol Metab       Date:  2019-04-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.